Pancreatic Cancer Research

ResearcherSahlgrenska University HospitalActive in the last 2 years

Svein Olav Bratlie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7968-9442; OpenAlex author ID A5074936530. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers

Papers 15

  1. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  2. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  3. Surveillance after surgery for pancreatic cancer: a global scoping review of guidelines and a nordic Survey of contemporary practice. Co-author DOI 10.1080/00365521.2024.2378948↗
  4. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  5. Impact of Surgery-Induced Myeloid-derived Suppressor Cells and the NOX2/ROS Axis on Postoperative Survival in Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0447↗
  6. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  7. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  8. PACADI: translation and adaptation of a Swedish-language version of the pancreatic cancer disease impact score. Last author DOI 10.1186/s13104-022-06199-6↗
  9. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  10. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  11. Preoperative Biliary Drainage Does Not Independently Reduce Survival After Pancreaticoduodenectomy Among Patients With Pancreatic Ductal Adenocarcinoma: A Nati… Co-author DOI 10.1097/as9.0000000000000090↗
  12. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  13. Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery? Co-author DOI 10.21037/jgo-2020-slapc-04↗
  14. How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer? First author DOI 10.21037/jgo-21-474↗
  15. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Knut Jørgen Labori · 3 shared papers, 2023–2025 · strength 0.47
  2. Elena B. Rangelova · 2 shared papers, 2021 · strength 0.45
  3. Marc G. Besselink · 3 shared papers, 2023–2025 · strength 0.44
  4. Bergþór Björnsson · 3 shared papers, 2021–2024 · strength 0.43
  5. Hanna E. Seppänen · 2 shared papers, 2024–2025 · strength 0.35
  6. Jakob Kirkegård · 3 shared papers, 2019–2024 · strength 0.34
  7. Izaak Quintus Molenaar · 2 shared papers, 2023–2024 · strength 0.26
  8. Bas Groot Koerkamp · 2 shared papers, 2023–2024 · strength 0.26
  9. Monika Fagevik Olsén · 1 shared paper, 2022 · strength 0.22
  10. Thomas Andersson · 1 shared paper, 2022 · strength 0.22
  11. Hanna Grauers Wiktorin · 1 shared paper, 2024 · strength 0.20
  12. Anna Martner · 1 shared paper, 2024 · strength 0.20
  13. Johan Bourghardt Fagman · 1 shared paper, 2024 · strength 0.20
  14. Hanneke W. Wilmink · 1 shared paper, 2025 · strength 0.19
  15. Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.19
  16. Peter Jo · 1 shared paper, 2025 · strength 0.19
  17. Bas A. Uijterwijk · 1 shared paper, 2025 · strength 0.19
  18. Pauli Antero Puolakkainen · 1 shared paper, 2025 · strength 0.19
  19. Jens Thomas Siveke · 1 shared paper, 2025 · strength 0.19
  20. Uwe Pelzer · 1 shared paper, 2025 · strength 0.19
  21. Alexander Otto König · 1 shared paper, 2025 · strength 0.19
  22. Olav Faisal Dajani · 1 shared paper, 2025 · strength 0.19
  23. Rickmer Braren · 1 shared paper, 2025 · strength 0.19
  24. Frank Viborg Mortensen · 2 shared papers, 2019–2021 · strength 0.18
  25. Stephen J. Wigmore · 2 shared papers, 2019–2021 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.